Showing results (151-160 of 165) with videos related to

Sort By:
Pageof 17
Plos One|April 8, 2021
Real world effectiveness of standard of care triple therapy versus two-drug combinations for treatment of people living with HIVRamón Teira, Helena Diaz-Cuervo, Filipa Aragão, et al.
Plos One|April 13, 2018
High quality of life, treatment tolerability, safety and efficacy in HIV patients switching from triple therapy to lopinavir/ritonavir monotherapy: A randomized clinical trialJuan Pasquau, Carmen Hidalgo-Tenorio, María Luisa Montes, et al.
Dermatologic Therapy|October 12, 2022
Secukinumab is effective and safe in the long-term treatment of plaque psoriasis in a daily practice setting: Multicenter study in 384 Spanish patientsPablo Chicharro, Mar Llamas-Velasco, Susana Armesto, et al.
Plos One|February 13, 2016
Effectiveness of Ritonavir-Boosted Protease Inhibitor Monotherapy in Clinical Practice Even with Previous Virological Failures to Protease Inhibitor-Based RegimensLuis F López-Cortés, Manuel A Castaño, Miguel A López-Ruz, et al.
International Journal of Dermatology|January 3, 2024
Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: a retrospective, multicenter cohort study in daily practice settingEsteban Daudén, Elena Escario, Luisa Martos-Cabrera, et al.
HIV Medicine|October 21, 2025
Clinical outcomes of long-acting cabotegravir and rilpivirine in people with HIV aged 60 and older: Real-world data from the Spanish RELATIVITY cohortJesús Troya, María Luisa Montes, María José Galindo, et al.
Antimicrobial Agents and Chemotherapy|December 13, 2021
Early Use of Sarilumab in Patients Hospitalized with COVID-19 Pneumonia and Features of Systemic Inflammation: the SARICOR Randomized Clinical TrialNicolás Merchante, Sheila Cárcel, José Carlos Garrido-Gracia, et al.
Open Forum Infectious Diseases|April 10, 2023
Role of IP-10 to Predict Clinical Progression and Response to IL-6 Blockade With Sarilumab in Early COVID-19 Pneumonia. A Subanalysis of the SARICOR Clinical TrialMarta Trigo-Rodríguez, Sheila Cárcel, Ana Navas, et al.
AIDS (London, England)|March 10, 2026
Determinants of long-acting cabotegravir plus rilpivirine discontinuation in real-world HIV care: insights from the RELATIVITY cohortJesús Troya, María Luisa Montes, María José Galindo, et al.
Lancet Regional Health. Americas|February 13, 2023
Cirrhosis etiology trends in developing countries: Transition from infectious to metabolic conditions. Report from a multicentric cohort in central MexicoAlex Gonzalez-Chagolla, Antonio Olivas-Martinez, Jesus Ruiz-Manriquez, et al.
Pageof 17